Broadstreet HEOR, Vancouver, BC, Canada.
Sarepta Therapeutics Inc, Cambridge MA; and.
J Clin Neuromuscul Dis. 2023 Dec 1;25(2):65-80. doi: 10.1097/CND.0000000000000461.
As the clinical course of autosomal recessive limb-girdle muscular dystrophy (LGMDR) is highly variable, this study characterized the frequency of loss of ambulation (LOA) among patients by subtype (LGMDR1, LGMDR2, LGMDR3-6, LGMDR9, LGMDR12) and progression to cardiac and respiratory involvement among those with and without LOA.
Systematic literature review.
From 2929 abstracts screened, 418 patients were identified with ambulatory status data (LOA: 265 [63.4%]). Cardiac and/or respiratory function was reported for 142 patients (34.0%; all with LOA). Among these, respiratory involvement was most frequent in LGMDR3-6 (74.1%; mean [SD] age 23.9 [11.0] years) and cardiac in LGMDR9 (73.3%; mean [SD] age 23.7 [17.7] years). Involvement was less common in patients without LOA except in LGMDR9 (71.4% respiratory and 52.4% cardiac).
This study described the co-occurrence of LOA, cardiac, and respiratory involvement in LGMDR and provides greater understanding of the clinical progression of LGMDR.
常染色体隐性遗传肢带型肌营养不良症(LGMDR)的临床病程变化较大,本研究通过亚型(LGMDR1、LGMDR2、LGMDR3-6、LGMDR9、LGMDR12)对丧失行走能力(LOA)患者的频率进行了特征描述,并对有无 LOA 的患者中出现心脏和呼吸受累的进展情况进行了描述。
系统文献回顾。
从筛选出的 2929 篇摘要中,共确定了 418 名具有步行状态数据的患者(LOA:265 [63.4%])。有 142 名患者(所有 LOA)报告了心脏和/或呼吸功能情况。在这些患者中,LGMDR3-6 中最常出现呼吸受累(74.1%;平均[SD]年龄 23.9[11.0]岁),LGMDR9 中最常出现心脏受累(73.3%;平均[SD]年龄 23.7[17.7]岁)。除 LGMDR9 外(呼吸受累 71.4%,心脏受累 52.4%),无 LOA 的患者中受累情况较少见。
本研究描述了 LGMDR 中 LOA、心脏和呼吸受累的共同发生情况,并进一步了解了 LGMDR 的临床进展。